Demographic and baseline characteristics
| Characteristic . | N = 20 (%) . |
|---|---|
| Median age (range), y | 62 (41-76) |
| Sex | |
| Male | 12 (60) |
| Female | 8 (40) |
| Race | |
| White | 18 (90) |
| Black | 2 (10) |
| T-LGLL–associated hematocytopenia (or indication for treatment) | |
| Neutropenia | 10 (50) |
| Transfusion-dependent anemia | 4 (20) |
| Symptomatic anemia | 2 (10) |
| Both | 4 (20) |
| STAT3 mutation∗ | |
| No | 13 (65) |
| Yes | 7 (35) |
| D661Y | 1 (5) |
| D661V | 1 (5) |
| Y640F | 3 (15) |
| N641I | 2 (10) |
| Concomitant autoimmune disease | |
| Rheumatoid arthritis | 1 (5) |
| Other† | 2 (10) |
| None | 17 (85) |
| Prior therapy (median, 2; range, 1-6) | |
| Methotrexate | 12 (60) |
| Cyclophosphamide | 7 (35) |
| Cyclosporine | 7 (35) |
| Alemtuzumab | 2 (10) |
| Pentostatin | 1 (5) |
| Tofacitinib | 1 (5) |
| No prior therapy | 7 (35) |
| Characteristic . | N = 20 (%) . |
|---|---|
| Median age (range), y | 62 (41-76) |
| Sex | |
| Male | 12 (60) |
| Female | 8 (40) |
| Race | |
| White | 18 (90) |
| Black | 2 (10) |
| T-LGLL–associated hematocytopenia (or indication for treatment) | |
| Neutropenia | 10 (50) |
| Transfusion-dependent anemia | 4 (20) |
| Symptomatic anemia | 2 (10) |
| Both | 4 (20) |
| STAT3 mutation∗ | |
| No | 13 (65) |
| Yes | 7 (35) |
| D661Y | 1 (5) |
| D661V | 1 (5) |
| Y640F | 3 (15) |
| N641I | 2 (10) |
| Concomitant autoimmune disease | |
| Rheumatoid arthritis | 1 (5) |
| Other† | 2 (10) |
| None | 17 (85) |
| Prior therapy (median, 2; range, 1-6) | |
| Methotrexate | 12 (60) |
| Cyclophosphamide | 7 (35) |
| Cyclosporine | 7 (35) |
| Alemtuzumab | 2 (10) |
| Pentostatin | 1 (5) |
| Tofacitinib | 1 (5) |
| No prior therapy | 7 (35) |